Badescu Minerva Codruta, Ciocoiu Manuela, Rezus Elena, Badulescu Oana Viola, Tanase Daniela Maria, Ouatu Anca, Dima Nicoleta, Ganceanu-Rusu Ana Roxana, Popescu Diana, Seritean Isac Petronela Nicoleta, Genes Tudor-Marcel, Rezus Ciprian
Department of Internal Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania.
III Internal Medicine Clinic, "St. Spiridon" County Emergency Clinical Hospital, 1 Independence Boulevard, 700111 Iasi, Romania.
Life (Basel). 2021 Oct 11;11(10):1072. doi: 10.3390/life11101072.
Advances in the treatment of hemophilia have made the life expectancy of hemophiliacs similar to that of the general population. Physicians have begun to face age-related diseases not previously encountered in individuals with hemophilia. Treatment of acute myocardial infarction (AMI) is particularly challenging because the therapeutic strategies influence both the patient's thrombotic and hemorrhagic risk. As progress has been made in the treatment of AMI over the last decade, we performed an in-depth analysis of the available literature, highlighting the latest advances in the therapy of AMI in hemophiliacs. It is generally accepted that after the optimal substitution therapy has been provided, patients with hemophilia should be treated in the same way as those in the general population. New-generation stents that allow short dual antiplatelet therapy and potent P2Y receptor inhibitors have begun to be successfully used. At a time when specific recommendations and relevant data are scarce, our study provides up-to-date information to physicians involved in the treatment of AMI in hemophiliacs.
血友病治疗方面的进展已使血友病患者的预期寿命与普通人群相近。医生们开始面对血友病患者以前未曾遇到的与年龄相关的疾病。急性心肌梗死（AMI）的治疗尤其具有挑战性，因为治疗策略会影响患者的血栓形成和出血风险。随着过去十年中AMI治疗取得进展，我们对现有文献进行了深入分析，突出了血友病患者AMI治疗的最新进展。人们普遍认为，在提供最佳替代疗法后，血友病患者应与普通人群患者接受相同的治疗方式。允许进行短程双联抗血小板治疗的新一代支架和强效P2Y受体抑制剂已开始成功应用。在特定建议和相关数据稀缺的情况下，我们的研究为参与血友病患者AMI治疗的医生提供了最新信息。
